Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: RETRACTED ARTICLE: Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders

Fig. 2

MSC-based therapy for treating GVHD. Owing to their exclusive immunomodulatory properties, MSC injection can restore clinical symptoms in GVHD in vivo. Mesenchymal stem/stromal cell (MSC); graft versus host diseases (GVHD); transforming growth factor-beta (TGF-β); hepatocyte growth factor (HGF); indoleamine 2,3-dioxygenase (IDO); cyclooxygenase-2 (COX-2); prostaglandin E2 (PGE2); programmed death receptor (PD); programmed death-ligand 1 (PD-L1); tumor necrosis factor-alpha (TNF-α), TNFα-stimulated gene-6 (TSG6); interferon-gamma (IFN-γ); immunoglobulin (Ig); T helper cell (Th); T regulatory cell (T reg); M1 and M2 macrophage (M1 and M2); natural killer cell (NKC); dendritic cell (DC); cytotoxic T lymphocyte (CTL)

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512